Sign up
Pharma Capital

VolitionRX prices stock offering at US$2.40 a share

The developer of blood tests to diagnose cancers intends to sell 3.5mln shares at US$2.40 a share
vials of blood in a lab
Proceeds would be used for product development and commercialisation and clinical studies

VolitionRx Ltd. (NYSE:VNRX) shares lost about one-fifth of their value Friday as the Belgium-based life sciences company announced plans to sell 3.5mln shares of its common stock in a public offering at a price of US$2.40.

The developer of blood tests designed to help diagnose a range of cancers said gross proceeds from the offering are expected to be about US$8.4mln before deducting for expenses.

VolitionRx also said it has granted the offering's underwriters a 30-day option to buy up to 525,000 additional shares to cover overallotments, if any. VolitionRx said it expects the offering to close on or about March 13.

READ: VolitionRx bolsters scientific advisory board with Harvard professor

Investors apparently were not pleased about the pending dilution of their holdings. They sent VolitionRx shares down 22% in premarket trading, to US$2.30 a share, and the pressure continued into the market open with shares down about 20% to US$2.38.

According to Yahoo Finance, VolitionRx currently has about 26.5mln shares outstanding.

The company said it intends to use net proceeds of the offering "for continued product development, clinical studies, product commercialisation, working capital and other general corporate purposes."

VolitionRx said a final prospectus supplement and an accompanying prospectus related to the proposed offering will be filed with the SEC and will be available on the SEC's website.

This story has been updated to include the number of shares offered and share price.

View full VNRX profile View Profile
View All

Related Articles

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.